Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
AssigneesIntegrated Biotherapeutics, Inc., University of Maryland, College Park
InventorsMohammad Javad Aman, Katie A. Howell, Frederick Wayne Holtsberg, Xuelian Zhao, Yuxing Li
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.
Claims12
An isolated antibody or antigen-binding fragment thereof comprising a binding domain that specifically binds to an epitope in the internal fusion loop of a Filovirus glycoprotein, wherein the binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL);
- (a) wherein the VH comprises heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3;
- wherein CDRH1 comprises SEQ ID NO:
- 3;
- wherein CDRH2 comprises SEQ ID NO:
- 4, and wherein CDRH3 comprises SEQ ID NO:
- 5;
- and
- (b) wherein the VL comprises light chain complementarity determining regions CDRL1, CDRL2, and CDRL3;
- wherein CDRL1 comprises SEQ ID NO:
- 6;
- wherein CDRL2 comprises SEQ ID NO:
- 7;
- and wherein CDRL3 comprises SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.